Guangzhou Bio-gene Technology Co., Ltd

This early-phase study tests a new type of cell therapy (CAR-T) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It is for people whose multiple myeloma has come back or stopped responding to treatment. The main goals are to check safety and find the right dose in 12…

This early-phase study tests a new treatment called BAFFR CAR-T for people with B-cell blood cancers (like certain leukemias and lymphomas) that did not get better or came back after standard treatments. The therapy uses a patient's own immune cells, modified to better find and a…

This early study tests a new treatment called BCMA-GPRC5D CAR-T for people with multiple myeloma that has returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The main goal is to check safety…